BioLife Solutions (BLFS) AI Stock Analysis

• Market Cap: $1.23B
• Dividend Yield: N/A
• Average Volume (3M): 545.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.00
• Revenue Growth: -18.61%
• EPS Growth: 92.36%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.33
• Shares Outstanding: 47,905,266
• 10 Day Avg. Volume: 614,867
• 30 Day Avg. Volume: 545,017
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 12.70
• Enterprise Value/Gross Profit: 15.36
• Enterprise Value/Ebitda: -120.37
• 1Y Price Target: $31.25
• Price Target Upside: 22.89% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 60 Neutral
• Price Target: $27.00 ▲(6.17% Upside)

BioLife Solutions' overall stock score is driven by strong revenue growth and positive technical indicators. However, challenges with profitability and valuation due to negative earnings and lack of dividend yield weigh down the score. The earnings call provided a positive outlook, but financial performance issues need addressing to improve the overall score.

Positive Factors

Financial Performance

Biolife reported 2Q25 results with revenue up 29% year-over-year, beating consensus estimates and showing strong financial performance.

Revenue Guidance

Management raised the 2025 revenue guidance to $100-103M, indicating confidence in continued growth and performance.

Strategic Expansion

The acquisition of PanTHERA Cryosolutions is part of Biolife's growth strategy, enhancing its product offerings and market position.

Negative Factors

Earnings

Despite the strong performance, the company still expects a reduction in net loss and expansion of Adj. EBITDA, with a path to Adj. EBITDA margin scaling into the 30%s long term.

Gross Margins

Gross margins fell a bit in the second quarter, to 62% from 64%.

BioLife Solutions Business Overview & Revenue Model

Company Description

BioLife Solutions (BLFS) is a leading provider of proprietary biopreservation tools and services for the cell and gene therapy sectors. The company specializes in the development and production of biopreservation media, cryopreservation solutions, and storage systems that ensure the viability and functionality of biologic materials during storage and transportation. Its core products include CryoStor, HypoThermosol, and other proprietary solutions designed to optimize the preservation of cellular therapies, tissue, and organs for transplantation.

How the Company Makes Money

BioLife Solutions generates revenue primarily through the sale of its biopreservation products and services to a diverse range of customers, including pharmaceutical companies, research institutions, and clinical laboratories involved in cell and gene therapy. Key revenue streams include direct sales of its proprietary media and cryopreservation solutions, as well as recurring revenue from long-term contracts with customers for product supply. The company also benefits from strategic partnerships with biotech firms and research organizations that enhance its market reach and product development capabilities. Additionally, BioLife Solutions may see increased earnings through collaborations that expand its product offerings and enter new markets, capitalizing on the growing demand for biopreservation solutions in the rapidly evolving life sciences sector.

BioLife Solutions Financial Statement Overview

Summary

BioLife Solutions is facing financial challenges with declining revenues and persistent losses impacting profitability. Despite a strong gross profit margin and a stable balance sheet with a high equity ratio, the negative net profit margin and revenue growth rate are concerning. However, improvements in cash flow suggest better cash management.

Income Statement

BioLife Solutions has faced challenges in maintaining revenue growth, with a decline from $161.76M in 2022 to $79.42M in TTM (Trailing-Twelve-Months). The gross profit margin is strong at 76.5% in TTM, but the company is struggling with profitability as indicated by a negative net profit margin of -13.1% and negative EBIT and EBITDA margins. The revenue growth rate is negative, reflecting a downward trend in sales.

Balance Sheet

The company's balance sheet shows a solid equity base with a high equity ratio of 89.2% in TTM, indicating financial stability. However, the debt-to-equity ratio is low at 0.08, suggesting limited leverage. The return on equity is negative due to ongoing losses, which is a concern for investors.

Cash Flow

BioLife Solutions has improved its cash flow position, with a positive free cash flow of $11.29M in TTM, up from $5.20M in 2024. The operating cash flow to net income ratio is positive, indicating efficient cash generation relative to net income losses. The company has managed to grow its free cash flow significantly, which is a positive sign despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	76.51M	82.25M	143.27M	76.24M	119.16M	48.09M
Gross Profit	63.25M	53.67M	46.75M	53.82M	37.75M	27.44M
EBITDA	-8.07M	1.53M	-45.24M	-124.18M	-16.65M	1.48M
Net Income	-5.53M	-20.18M	-66.43M	-139.81M	-8.91M	2.67M
Balance Sheet
Total Assets	387.24M	399.49M	412.71M	450.23M	552.60M	234.83M
Cash, Cash Equivalents and Short-Term Investments	81.77M	104.58M	51.70M	62.70M	69.87M	90.46M
Total Debt	23.82M	30.17M	42.69M	43.71M	26.88M	11.15M
Total Liabilities	40.09M	50.58M	75.05M	86.04M	71.85M	29.58M
Stockholders Equity	347.15M	348.91M	337.66M	364.19M	480.75M	205.25M
Cash Flow
Free Cash Flow	11.45M	5.20M	-18.88M	-18.87M	-13.22M	1.88M
Operating Cash Flow	15.54M	8.43M	-12.50M	-8.49M	-4.84M	6.51M
Investing Cash Flow	5.25M	58.30M	17.84M	-58.12M	-12.64M	-23.73M
Financing Cash Flow	-11.00M	-6.78M	10.59M	16.32M	-2.78M	102.08M

BioLife Solutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Positive. The current price of 25.43 is above the 20-day moving average (MA) of 23.58, above the 50-day MA of 22.51, and above the 200-day MA of 24.32, indicating a bullish trend. The MACD of 0.99 indicates Negative momentum. The RSI at 63.40 is Neutral, neither overbought nor oversold. The STOCH value of 68.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLFS.

BioLife Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLFS	60 Neutral	$1.23B	―	-5.98%	―	-18.61%	92.36%
STAA	56 Neutral	$1.36B	55.81	-25.55%	―	-32.59%	-667.81%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
AZTA	48 Neutral	$1.40B	―	-1.74%	―	-8.15%	13.50%
PLSE	44 Neutral	$1.14B	―	-103.50%	―	―	-33.24%
NNNN	―	$7.10B	813.86	15.00%	―	―	―
KMTS	45 Neutral	$951.75M	―	-130.38%	―	115.05%	-21.37%

BioLife Solutions Corporate Events

BioLife Solutions Strengthens Board with Tony J. Hunt Appointment

BioLife Solutions has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors effective January 2, 2025. Mr. Hunt, recognized for his leadership in bioprocessing innovation, is expected to enhance BioLife’s strategic focus on the CGT market with his extensive industry experience, contributing to the company’s growth and innovation efforts. This appointment reflects BioLife’s commitment to strengthening its position in the bioprocessing sector and supporting its mission of delivering top-tier bioproduction workflows.